Business Description
Xbrane Biopharma AB
ISIN : SE0026598583
Total Employee Number:
29Compare
Compare
Traded in other countries / regions
XBRANE.Sweden7XB0.GermanyXBRANs.UK IPO Date
2020-11-05Description
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. The company's product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. Other products in preclinical stage of the company includes Xdivane and Xdarzane.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.78 | |||||
Equity-to-Asset | 0.84 | |||||
Debt-to-Equity | 0.12 | |||||
Debt-to-EBITDA | -0.94 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -0.55 | |||||
Beneish M-Score | 2.83 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -33.8 | |||||
3-Year EBITDA Growth Rate | 80.8 | |||||
3-Year EPS without NRI Growth Rate | 62.8 | |||||
3-Year FCF Growth Rate | 44.8 | |||||
3-Year Book Growth Rate | -50.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 28.91 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 24.43 | |||||
9-Day RSI | 32.14 | |||||
14-Day RSI | 36.69 | |||||
3-1 Month Momentum % | -15.86 | |||||
6-1 Month Momentum % | 63.83 | |||||
12-1 Month Momentum % | -58.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.19 | |||||
Quick Ratio | 1.45 | |||||
Cash Ratio | 0.49 | |||||
Days Inventory | 929.71 | |||||
Days Sales Outstanding | 43.48 | |||||
Days Payable | 204.19 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -119.8 | |||||
Shareholder Yield % | 37.44 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 7.1 | |||||
Operating Margin % | -81.29 | |||||
Net Margin % | -90.04 | |||||
EBITDA Margin % | -81.29 | |||||
FCF Margin % | -264.1 | |||||
OCF Margin % | -156.39 | |||||
ROE % | -14.3 | |||||
ROA % | -11.4 | |||||
ROIC % | -12.22 | |||||
3-Year ROIIC % | 99.76 | |||||
ROC (Joel Greenblatt) % | -58.53 | |||||
ROCE % | -12.62 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 0.81 | |||||
PS Ratio | 2.59 | |||||
PB Ratio | 0.36 | |||||
Price-to-Tangible-Book | 0.86 | |||||
EV-to-EBIT | -3.01 | |||||
EV-to-Forward-EBIT | -6.05 | |||||
EV-to-EBITDA | -3.01 | |||||
EV-to-Forward-EBITDA | -6.05 | |||||
EV-to-Revenue | 2.44 | |||||
EV-to-Forward-Revenue | 1.81 | |||||
EV-to-FCF | -0.95 | |||||
Price-to-GF-Value | 1.58 | |||||
Price-to-Median-PS-Value | 0.15 | |||||
| Price-to-Net-Current-Asset-Value | 0.88 | |||||
Earnings Yield (Greenblatt) % | -33.19 | |||||
FCF Yield % | -116.16 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Xbrane Biopharma AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 7.629 | ||
| EPS (TTM) (€) | -0.341 | ||
| Beta | -1.5398 | ||
| 3-Year Sharpe Ratio | 0.49 | ||
| 3-Year Sortino Ratio | 1.53 | ||
| Volatility % | 111.72 | ||
| 14-Day RSI | 36.69 | ||
| 14-Day ATR (€) | 0.014804 | ||
| 20-Day SMA (€) | 0.8186 | ||
| 12-1 Month Momentum % | -58.36 | ||
| 52-Week Range (€) | 0.4508 - 5.0375 | ||
| Shares Outstanding (Mil) | 20.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Xbrane Biopharma AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Xbrane Biopharma AB Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-19 | In 176 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-19 | In 176 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-30 | In 64 days | ||
| Third quarter earnings results for 2026 | 2026-10-30 | In 64 days | ||
| Second quarter earnings results for 2026 | 2026-07-17 | 0.89 (+0.00%) | ||
| Second quarter earnings conference call for 2026 | 2026-07-17 | 0.89 (+0.00%) | ||
| General meeting for 2025 | 2026-05-05 16:00 | 0.94 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-05 | 0.94 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 0.94 (+0.00%) | ||
| Annual report for 2025 | 2026-03-31 | 0.48 (+0.00%) |
Show
Entries
Xbrane Biopharma AB Frequently Asked Questions
What is Xbrane Biopharma AB(FRA:7XB0)'s stock price today?
The current price of FRA:7XB0 is €0.77. The 52 week high of FRA:7XB0 is €5.04 and 52 week low is €0.45.
When is next earnings date of Xbrane Biopharma AB(FRA:7XB0)?
The next earnings date of Xbrane Biopharma AB(FRA:7XB0) is 2026-10-30.
Does Xbrane Biopharma AB(FRA:7XB0) pay dividends? If so, how much?
Xbrane Biopharma AB(FRA:7XB0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Xbrane Biopharma AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers